Peptides: What Is Approved, What Is Not, and What the Evidence Shows

The peptides that are FDA-approved

Several of the most consequential drugs of the last decade are peptides, and they are approved, manufactured under pharmaceutical quality controls, and prescribed by licensed providers.

• GLP-1 receptor agonists. Semaglutide and tirzepatide are peptide drugs, and they are the most rigorously studied entries in this whole space, with large cardiovascular and weight outcome trials behind them. If you arrived at peptides through weight loss, this is the evidence-backed path and it is covered in depth on the weight loss hub.
• Tesamorelin. A growth hormone releasing factor analogue, FDA-approved specifically to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. That narrow indication is the approved one; broader "body composition" use is off-label.
• hCG. Human chorionic gonadotropin is an approved peptide hormone, used in fertility care and sometimes alongside testosterone therapy to preserve testicular function. It is discussed on the testosterone hub.
• Insulin, and a long list of others. Insulin, octreotide, leuprolide and many more have been standard therapy for decades. The point is that peptide drugs are not fringe. Approved ones are ordinary medicine.

What these share is an approval file: identified indication, established dosing, characterized side effects, and a manufacturer accountable for what is in the vial.

The peptides that are not approved, and what that actually means

The compounds driving most of the current online interest are in a different position entirely. BPC-157, ipamorelin, CJC-1295, and a long tail of similar molecules are not FDA-approved for human use in the United States. Some have interesting preclinical data, mostly in animals. Some have no meaningful human evidence at all. None have the outcome trials that would let anyone honestly tell you what they do over years.

In 2023 the FDA placed several of these, BPC-157 among them, into Category 2 of its 503A bulk drug substances list, the bucket for substances with significant safety risks, which effectively closed the door on compounding pharmacies preparing them legally. That is why supply moved to vendors selling vials labelled "research use only, not for human consumption." That label is not a formality or a wink. It is the legal mechanism by which those products avoid being regulated as drugs, and it means no agency is checking what is in them.

The practical consequences are worth stating plainly:

• Purity is unverified. Independent testing of gray-market peptide products has repeatedly found wrong quantities, degraded product, and contaminants including bacterial endotoxin. You are injecting something whose contents nobody has certified.
• Dosing is folklore. Protocols circulating in forums are not derived from human dose-finding studies, because for most of these compounds those studies do not exist.
• Long-term safety is unknown. Several of these compounds act on growth and repair pathways. "Promotes tissue growth" is an appealing claim right up until you ask what else it might promote in someone with an undiagnosed cancer. Absence of evidence of harm is not evidence of safety.
• Interactions are uncharacterized. Nobody has studied how these behave alongside your other medications.

None of that means every unapproved peptide is dangerous. It means nobody can currently tell you that it is not, and anyone selling you one while claiming otherwise is telling you something they cannot know.

Why the marketing is so persuasive

The pitch works because it contains real things. Peptide drugs genuinely did transform metabolic medicine. Signaling molecules genuinely are a legitimate and active area of pharmaceutical research. The mechanism stories are genuinely plausible on paper.

The move to watch for is the slide from that true general premise to a specific unproven product. "Peptides are the future of medicine, therefore this vial is good for your shoulder" skips the step where somebody demonstrates that this vial does that thing safely in people. Plausible mechanism is where drug development starts, not where it finishes, and the history of medicine is substantially a history of mechanistically elegant ideas that failed in trials.

Be especially wary of a few specific patterns: before-and-after photography, testimonial volume standing in for trial data, "clinically studied" attached to a compound with only rodent data, and any vendor who both sells you the product and tells you how to dose it.

If you are going to explore this anyway

People will, so the useful thing is harm reduction rather than a lecture.

• Tell your actual doctor. Not for permission, for safety. They cannot account for an interaction or interpret a strange lab result if they do not know what you are taking.
• Start from the approved options. If the goal is fat loss, an approved GLP-1 under supervision has evidence a research peptide does not. If the goal is energy, drive, or recovery, get the baseline bloodwork first, because the answer is frequently thyroid, sleep, or hormones rather than anything exotic.
• Treat an injury as an injury. The tissue-repair claims draw people with tendon and joint problems. Those deserve imaging and a physical therapist, not a vial. A peptide that masks pain while you keep loading a damaged tendon makes the outcome worse.
• Watch for the things that need a doctor now. Injection-site infection, an allergic reaction, unexplained swelling, or new numbness or weakness are not "adjustment periods."

Where this is heading

The honest forecast is that some of these compounds will turn out to be useful and will go through trials and approval, and others will quietly disappear the way most candidate drugs do. Peptide therapeutics is a serious field, and the approved drugs already on the market are the proof. The gap is not between peptides and real medicine. It is between the peptides that have been tested and the ones being sold ahead of the evidence.

We will expand this hub as compounds move through the approval pipeline, and we will say so plainly when one does. OmenRx publishes education only. We do not prescribe, sell, or dispense anything, we do not link to research-chemical suppliers, and eligibility for any prescription medication is always decided by a licensed provider.